Watch HRMY. Know when insiders buy.
One email the day a filing lands. Free.
HRMY
Harmony Biosciences Holdings, Inc.
41.62
−0.45 −1.07%
USD · close Sep 9
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
49
WATCH · insiders 25, shorts 72
Insiders, 90 days
−$1.5M
net selling · 0 buys, 4 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.4BP/E 13.5DIV YIELD —FCF YIELD —REV TTM $959.9M +24.3%NET INCOME $181.3M +0.2%NET CASH $395.8M52W 25.90 – 42.86SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $261.3M | +30.3% | 75.8% | $89.3M | $75.4M | +89.6% | 1.28 | $92.4M | — | — | Aug 4 |
| Q1 2026 · Mar 31 | $215.4M | +16.6% | 79.3% | $37.3M | $32.5M | −28.7% | 0.55 | $27.8M | — | — | May 7 |
| Q4 2025 · Dec 31derived | $243.8M | +21.1% | 71.9% | $38.6M | $22.5M | −54.6% | 0.39 | $126.2M | $107K | $126M | Feb 24 |
| Q3 2025 · Sep 30 | $239.5M | +28.7% | 75.1% | $65.5M | $50.9M | +10.4% | 0.87 | $108.7M | $71K | $108.7M | Nov 4 |
| Q2 2025 · Jun 30 | $200.5M | +16.0% | 81.0% | $48.2M | $39.8M | +243.2% | 0.68 | $79.3M | $4K | $79.3M | Aug 4 |
| Q1 2025 · Mar 31 | $184.7M | +19.5% | 82.7% | $56.2M | $45.6M | +18.9% | 0.78 | $34M | $128K | $33.9M | May 7 |
| Q4 2024 · Dec 31derived | $201.3M | +19.5% | 73.0% | $55.7M | $49.5M | +85.9% | 0.85 | $75.6M | $513K | $75M | Feb 24 |
| Q3 2024 · Sep 30 | $186M | +16.1% | 77.0% | $61.7M | $46.1M | +19.8% | 0.79 | $70.5M | $3K | $70.5M | Nov 4 |
| Q2 2024 · Jun 30 | $172.8M | — | 81.4% | $21.4M | $11.6M | — | 0.20 | $42.6M | $632K | $42M | Aug 5 |
| Q1 2024 · Mar 31 | $154.6M | — | 82.2% | $52M | $38.3M | — | 0.67 | $31.1M | $5K | $31.1M | May 6 |
| Q4 2023 · Dec 31derived | $168.4M | — | 74.4% | $40.2M | $26.6M | — | 0.45 | $76.7M | $107K | $76.6M | Feb 24 |
| Q3 2023 · Sep 30 | $160.3M | — | 79.8% | $64.5M | $38.5M | — | 0.63 | $63.1M | $0 | $63.1M | Oct 29 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $868.5M | 77.2% | $208.5M | $158.7M | 18.3% | 2.71 | $348.2M | $310K | $347.9M | — | — |
| FY2024 · to Dec 31 | $714.7M | 78.1% | $190.8M | $145.5M | 20.4% | 2.51 | $219.8M | $1.2M | $218.7M | — | — |
| FY2023 · to Dec 31 | $582M | 79.2% | $192M | $128.9M | 22.1% | 2.13 | $219.4M | $312K | $219.1M | $100M | — |
| FY2022 · to Dec 31 | $437.9M | 80.9% | $120.2M | $181.5M | 41.4% | 2.97 | $144.5M | $172K | $144.3M | — | — |
| FY2021 · to Dec 31 | $305.4M | 81.8% | $87.5M | $34.6M | 11.3% | 0.58 | $98.6M | $298K | $98.3M | — | — |
| FY2020 · to Dec 31 | $159.7M | 82.6% | $17M | −$36.9M | -23.1% | -2.48 | −$3M | $2K | −$3M | $167K | — |
Every number comes from Harmony Biosciences Holdings, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.